[FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].

Abstract excerpt

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene represent the most common genetic alteration in acute myeloid leukemia (AML), identified in approximately one third of patients newly diagnosed with AML. FLT3 internal tandem duplication mutations (FLT3-ITD) are associated with increased relapse and inferior overall survival. Multiple inhibitors of FLT3 signaling have been developed in the last few years...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to fms-Like Tyrosine Kinase 3
• Share to Hematopoietic Stem Cell Transplantation